News
Skye Bioscience
SKYE · NASDAQ
$1.62+$0.09 (+5.88%)TodayMarket closed ·
Prev close $1.53
Latest news
- NewsTanya Rawat
Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move
- Press releaseGlobe Newswire
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
- Press releaseGlobe Newswire
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
- Press releaseGlobe Newswire
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseGlobe Newswire
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
- Press releaseGlobe Newswire
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
- Press releaseGlobe Newswire
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why Domo Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- News
Earnings Scheduled For March 10, 2026
- News
A Peek at Skye Bioscience's Future Earnings
- Press releaseGlobe Newswire
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Semtech Corporation (SMTC), Six Flags Entertainment Corporation (FUN), Skye Bioscience, Inc. (SKYE), and Stride, Inc. (LRN)
- NewsVandana Singh
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year
- Press releaseGlobe Newswire
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
- Press releasePRNewswire
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE
- Press releasePRNewswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releasePRNewswire
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit
- Press releaseGlobe Newswire
SKYE BIOSCIENCE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th
- Press releasePRNewswire
Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm
- Press releaseGlobe Newswire
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
- Press releasePRNewswire
Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE
- Press releasePRNewswire
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE
- Press releasePRNewswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releasePRNewswire
FRIDAY DEADLINE: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026
- Press releaseGlobe Newswire
SKYE BIOSCIENCE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th
- News
Skye Bioscience Issues 2026 Corporate Outlook Outlining Planned Clinical, Manufacturing, And Corporate Milestones To Advance Nimacimab, Skye's Peripherally Restricted CB1-Inhibiting Antibody
- Press releaseGlobe Newswire
Skye Provides 2026 Corporate Outlook
- Press releasePRNewswire
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit
- Press releaseBusiness Wire
SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights
- Press releaseGlobe Newswire
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
- Press releasePRNewswire
Investors who lost money on Skye Bioscience, Inc.(SKYE) should contact Levi & Korsinsky about pending Class Action - SKYE
- Press releasePRNewswire
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYE
- Press releasePRNewswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit
- Press releasePRNewswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit
- Press releaseGlobe Newswire
SKYE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Skye Bioscience, Inc. and Encourages Investors to Contact the Firm
- Press releasePRNewswire
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
- Press releaseGlobe Newswire
Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors
- NewsAvi Kapoor
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
- NewsAvi Kapoor
US Stocks Mixed; Dow Falls 100 Points
- NewsAvi Kapoor
Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.